Pet insurance is worth it when a single large claim would exceed the premiums you would pay over the pet's life, and it is not worth it as a way to come out ahead on routine care. A US accident-and-illness policy averaged $749.29 a year for dogs and $386.47 a year for cats in 2024 [NAPHIA State of the Industry, Average Premiums, 2024]. One cruciate-ligament surgery averages $3,525 and runs to $6,417 by region [CareCredit: How Much Does CCL (ACL) Surgery for Dogs Cost?, 2025], the kind of bill the premium is bought to cover.
The short answer
For a healthy young pet, pet insurance is catastrophe protection: most years you pay the premium and claim little, and the value sits entirely in the year a $4,000 surgery or a multi-thousand-dollar cancer course lands. For a pet that already has a diagnosis, it is usually not worth buying for that condition at all, because every major US sample policy excludes pre-existing conditions and the NAIC Pet Insurance Model Act defines one as any condition for which advice or treatment was received before the policy date or during a waiting period [NAIC: NAIC Passes Pet Insurance Model Act, 2022].
The honest framing comes from the buyer data. Consumer Reports surveyed 3,583 pet-insurance policyholders and found only 44% received full reimbursement at their policy level after the copay on their most recent claims, with a median premium among CR members of $34.50 a month [Brian Vines, Consumer Reports Pet Insurance Buying Guide, 2026]. Worth-it is not "does it pay something." It is "does the structure pay enough, on the claim you are exposed to, to beat what the premiums would have grown to." That answer is conditional, and this guide walks the conditions.
When pet insurance is worth it
The case is strongest for an owner whose realistic risk is one expensive, possibly recurring condition. Run the comparison against the cost data, not against a feeling. A cruciate-ligament repair averages $3,525 and reaches $6,417 in higher-cost regions; an intestinal-blockage (foreign body) surgery for a dog averages $4,383 and ranges to $7,976 [CareCredit: Intestinal Blockage Surgery Cost for Dogs and Cats, 2025]. A dog lymphoma chemotherapy course averages $5,254 and the broader range for cancer treatment runs $3,000 to $10,000 or more over several months [CareCredit: How Much Does Chemotherapy Cost for Dogs and Cats?, 2025].
At an 80% reimbursement and a $500 annual deductible, a $5,000 covered claim returns roughly $3,600 the year it happens. Against a dog premium near the NAPHIA average of $749 a year, one such claim recovers four to five years of premiums in a single payout. The math works decisively when the claim is large and the policy structure does not cap it short. A no-annual-limit structure keeps paying on a long cancer course or a multi-year orthopedic condition where a $10,000 cap would run out mid-treatment; that is the central reason an owner of a breed with a known orthopedic risk is the textbook worth-it buyer.
Enrollment timing decides whether the math is even available. A condition that surfaces during a waiting period or before enrollment becomes pre-existing and is excluded, so the policy is worth most when bought on a young, asymptomatic pet, before the records carry anything an insurer can link to a later claim.
When it is not worth it
Pet insurance is a poor purchase in three situations, and the cited reasons matter more than the intuition.
- When the only goal is recouping routine care. Wellness and preventive care are excluded from the base accident-and-illness policy at the major providers and are sold, if at all, as a separate non-insurance add-on. Embrace's Wellness Rewards, for example, is an optional membership with an annual benefit of $300, $500, or $700 that you select and largely get back as the routine spend you would have had anyway [Embrace Pet Insurance: Wellness Rewards, 2026]. Paying an insurer to hand back roughly what you put in is not insurance; it is a budgeting wrapper with overhead.
- When the pet already has the condition you are insuring against. The pre-existing exclusion has no general curable-condition carve-out in the model framework, so buying a policy the week after a diagnosis will not cover that diagnosis. It can still be worth buying for future unrelated conditions, but it is not worth it as a fix for the bill in front of you.
- When partial reimbursement quietly erodes the value. The Consumer Reports finding that fewer than half of policyholders got full reimbursement at their policy level traces to specific terms: an exam-fee carve-out that makes you pay the consultation on every visit, an annual cap that stops mid-claim, or a per-condition deductible that triggers repeatedly in a multi-problem year. A buyer with many small recurring bills rather than one catastrophic one frequently pays more in premiums plus carve-outs than they recover.
How to run the math for your pet
Do not compare the premium to nothing. Compare the lifetime premium to the expected value of the claims the structure would pay, and stress-test it against one catastrophic year.
Start with the annual premium for your pet's species, age, and state, then multiply by a realistic holding period. A dog at the NAPHIA 2024 average of $749 a year held eight years is roughly $6,000 in premiums, before age-based increases. Then ask: across eight years, is one $4,000-to-$7,000 surgical or oncology event plausible for this breed and age? The CareCredit ranges above are the inputs. If yes, the policy is likely worth it provided the structure does not cap the payout below the bill.
Then apply the structure to a worked claim. On a $5,000 covered claim at 80% reimbursement and a $500 deductible, you recover about $3,600. On a no-annual-limit plan that figure holds even if the same condition recurs next year; on a $10,000-cap plan a $12,000 cancer course leaves $2,000 plus next year's recurrence unreimbursed. The deductible type is the other lever: an annual deductible is met once per policy year across conditions, while a per-condition deductible is met once per condition for life, which is generous for one chronic illness and punishing in a year with several unrelated problems.
Dog A&I premium at the 2024 US average: $749.29 a year [NAPHIA State of the Industry, Average Premiums, 2024]. Over 8 years, before age increases, that is roughly $5,994 in premiums.
One cruciate-ligament surgery in year 4 at the $3,525 national average, reimbursed at 80% after a $500 annual deductible, returns about $2,420 that year. A second unrelated $4,383 foreign-body surgery in year 6 returns about $3,106 more [CareCredit: Intestinal Blockage Surgery Cost for Dogs and Cats, 2025]. Two plausible orthopedic-or-surgical events across 8 years return roughly $5,500 against roughly $6,000 in premiums, and the case turns clearly positive if a third event or a cancer course lands. With zero major events, the $5,994 is the cost of the protection.
The honest conclusion from the math: pet insurance is close-to-break-even in the expected case and strongly positive in the bad case.
That is exactly what insurance is supposed to be. It is the wrong product if you need it to be positive every year.
Where to start
If your pet is young and asymptomatic and your concern is one large future bill, the worth-it case favors a structure that does not cap the payout. Healthy Paws built its plan around no-payout-limit options, and Trupanion pairs a flat 90% reimbursement with no annual, per-condition, or lifetime cap, which is why both suit the catastrophe buyer, weighed against the exam-fee and deductible-type tradeoffs each carries. If you are optimizing lifetime cost on a healthy young pet and can accept a benefit ceiling you are unlikely to hit, a lower-premium tiered plan like Lemonade usually wins the multi-year hold. If a six-month orthopedic waiting period is the term you are worried about, Embrace lets you cut it to as few as 14 days with a post-purchase vet exam.
Before buying anything, read how pet insurance works so the reimbursement model and the exclusions are not a surprise at claim time, and use how to choose pet insurance as the term-by-term checklist. The review method is published at /methodology/. FurVerdict is an independent editorial site and is not a licensed insurance agent; verify current terms with the provider before purchasing.